---
title: "US Stock Market Movement | Merck falls more than 10% after lowering adjusted earnings per share expectations"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/210226574.md"
description: "On Tuesday, Merck opened lower and fell more than 10% as of the time of publication, trading at $114.9. The company lowered its adjusted earnings per share expectations. Merck's Q2 revenue was $16.11 billion, a 7% year-on-year increase, with market expectations at $15.84 billion. The company revised its adjusted earnings per share expectations from the previous $8.53 to $8.65 down to $7.94 to $8.04. This adjustment reflects one-time costs related to the acquisitions of Harpoon Therapeutics and EyeBio, at $0.26 and $0.51 per share, respectively"
datetime: "2024-07-30T15:07:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/210226574.md)
  - [en](https://longbridge.com/en/news/210226574.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/210226574.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/210226574.md) | [繁體中文](https://longbridge.com/zh-HK/news/210226574.md)


# US Stock Market Movement | Merck falls more than 10% after lowering adjusted earnings per share expectations

According to the Zhitong Finance and Economics APP, on Tuesday, Merck (MRK.US) opened low and continued to decline, with the stock falling more than 10% to $114.9 as of the time of publication. The company has lowered its adjusted earnings per share expectations.

Merck's Q2 revenue was $16.11 billion, a 7% year-on-year increase, exceeding market expectations of $15.84 billion. The company has revised its adjusted earnings per share guidance from the previous range of $8.53 to $8.65 down to $7.94 to $8.04. Merck stated that this adjustment reflects one-time expenses related to the acquisitions of Harpoon Therapeutics and EyeBio, which are $0.26 and $0.51 per share, respectively

### Related Stocks

- [Merck & Co., Inc. (MRK.US)](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

- [Infinimmune, Merck enter into antibody discovery pact](https://longbridge.com/en/news/281193725.md)
- [Merck & Co. Touts $6.7B Terns Deal, Highlights TERN-701 “Best-in-Class” CML Potential](https://longbridge.com/en/news/280868524.md)
- [Hershey Stock (HSY) Looks Sweeter After Company Promises Return to Classic Reese's](https://longbridge.com/en/news/281415413.md)
- [OPEC oil output plunges in March as war forces export cuts, Reuters survey finds](https://longbridge.com/en/news/281209047.md)
- [Nike's results were better than expected, but investors still aren't sold on its turnaround](https://longbridge.com/en/news/281245718.md)